Cargando…
Current and Future Approaches for Monitoring Responses to Anti-complement Therapeutics
Aberrations in complement system functions have been identified as either direct or indirect pathophysiological mechanisms in many diseases and pathological conditions, such as infections, autoimmune diseases, inflammation, malignancies, and allogeneic transplantation. Currently available techniques...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6856077/ https://www.ncbi.nlm.nih.gov/pubmed/31787968 http://dx.doi.org/10.3389/fimmu.2019.02539 |
_version_ | 1783470502125240320 |
---|---|
author | Mohebnasab, Maedeh Eriksson, Oskar Persson, Barbro Sandholm, Kerstin Mohlin, Camilla Huber-Lang, Markus Keating, Brendan J. Ekdahl, Kristina N. Nilsson, Bo |
author_facet | Mohebnasab, Maedeh Eriksson, Oskar Persson, Barbro Sandholm, Kerstin Mohlin, Camilla Huber-Lang, Markus Keating, Brendan J. Ekdahl, Kristina N. Nilsson, Bo |
author_sort | Mohebnasab, Maedeh |
collection | PubMed |
description | Aberrations in complement system functions have been identified as either direct or indirect pathophysiological mechanisms in many diseases and pathological conditions, such as infections, autoimmune diseases, inflammation, malignancies, and allogeneic transplantation. Currently available techniques to study complement include quantification of (a) individual complement components, (b) complement activation products, and (c) molecular mechanisms/function. An emerging area of major interest in translational studies aims to study and monitor patients on complement regulatory drugs for efficacy as well as adverse events. This area is progressing rapidly with several anti-complement therapeutics under development, in clinical trials, or already in clinical use. In this review, we summarized the appropriate indications, techniques, and interpretations of basic complement analyses, exemplified by a number of clinical disorders. |
format | Online Article Text |
id | pubmed-6856077 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-68560772019-11-29 Current and Future Approaches for Monitoring Responses to Anti-complement Therapeutics Mohebnasab, Maedeh Eriksson, Oskar Persson, Barbro Sandholm, Kerstin Mohlin, Camilla Huber-Lang, Markus Keating, Brendan J. Ekdahl, Kristina N. Nilsson, Bo Front Immunol Immunology Aberrations in complement system functions have been identified as either direct or indirect pathophysiological mechanisms in many diseases and pathological conditions, such as infections, autoimmune diseases, inflammation, malignancies, and allogeneic transplantation. Currently available techniques to study complement include quantification of (a) individual complement components, (b) complement activation products, and (c) molecular mechanisms/function. An emerging area of major interest in translational studies aims to study and monitor patients on complement regulatory drugs for efficacy as well as adverse events. This area is progressing rapidly with several anti-complement therapeutics under development, in clinical trials, or already in clinical use. In this review, we summarized the appropriate indications, techniques, and interpretations of basic complement analyses, exemplified by a number of clinical disorders. Frontiers Media S.A. 2019-11-08 /pmc/articles/PMC6856077/ /pubmed/31787968 http://dx.doi.org/10.3389/fimmu.2019.02539 Text en Copyright © 2019 Mohebnasab, Eriksson, Persson, Sandholm, Mohlin, Huber-Lang, Keating, Ekdahl and Nilsson. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Mohebnasab, Maedeh Eriksson, Oskar Persson, Barbro Sandholm, Kerstin Mohlin, Camilla Huber-Lang, Markus Keating, Brendan J. Ekdahl, Kristina N. Nilsson, Bo Current and Future Approaches for Monitoring Responses to Anti-complement Therapeutics |
title | Current and Future Approaches for Monitoring Responses to Anti-complement Therapeutics |
title_full | Current and Future Approaches for Monitoring Responses to Anti-complement Therapeutics |
title_fullStr | Current and Future Approaches for Monitoring Responses to Anti-complement Therapeutics |
title_full_unstemmed | Current and Future Approaches for Monitoring Responses to Anti-complement Therapeutics |
title_short | Current and Future Approaches for Monitoring Responses to Anti-complement Therapeutics |
title_sort | current and future approaches for monitoring responses to anti-complement therapeutics |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6856077/ https://www.ncbi.nlm.nih.gov/pubmed/31787968 http://dx.doi.org/10.3389/fimmu.2019.02539 |
work_keys_str_mv | AT mohebnasabmaedeh currentandfutureapproachesformonitoringresponsestoanticomplementtherapeutics AT erikssonoskar currentandfutureapproachesformonitoringresponsestoanticomplementtherapeutics AT perssonbarbro currentandfutureapproachesformonitoringresponsestoanticomplementtherapeutics AT sandholmkerstin currentandfutureapproachesformonitoringresponsestoanticomplementtherapeutics AT mohlincamilla currentandfutureapproachesformonitoringresponsestoanticomplementtherapeutics AT huberlangmarkus currentandfutureapproachesformonitoringresponsestoanticomplementtherapeutics AT keatingbrendanj currentandfutureapproachesformonitoringresponsestoanticomplementtherapeutics AT ekdahlkristinan currentandfutureapproachesformonitoringresponsestoanticomplementtherapeutics AT nilssonbo currentandfutureapproachesformonitoringresponsestoanticomplementtherapeutics |